Head-to-head evidence
Ganaxolone vs Stiripentol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Ganaxolone
Marketed by Immedica Pharma AB
NCT01963208 · Phase 3 · completed
The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.
Stiripentol
Marketed by Biocodex
NCT07176832 · Phase 1 · completed
This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ganaxolone's landscape · Stiripentol's landscape